Ligand Pharma (LGND) Tops Q4 EPS by 16c; Issues Light Q1 Outlook

February 11, 2014 8:32 AM

Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.35, $0.16 better than the analyst estimate of $0.19. Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found